Zacks Investment Research cut shares of Signal Genetics Inc (NASDAQ:SGNL) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York. “

Separately, Rodman & Renshaw set a $4.00 price target on shares of Signal Genetics and gave the company a buy rating in a research note on Sunday, August 21st.

Signal Genetics (NASDAQ:SGNL) traded up 4.26% on Wednesday, hitting $0.49. The stock had a trading volume of 18,523 shares. The firm’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.52. Signal Genetics has a 12 month low of $0.40 and a 12 month high of $1.24. The stock’s market cap is $5.29 million.

Signal Genetics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

5 Day Chart for NASDAQ:SGNL

Receive News & Stock Ratings for Signal Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc and related stocks with our FREE daily email newsletter.